Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612586 · ClinicalTrials.gov registry record · Phase 2
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT00612586 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 117 participants.
The verdict
NCT00612586, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV + irinotecan (FOLFIRI), plus bevacizumab in patients with Metastatic Colorectal Cancer.
Interventions
- DRUG Placebo
- DRUG Leucovorin (LV)
- DRUG 5-fluorouracil (5-FU)
- DRUG Enzastaurin
- DRUG Bevacizumab (Bev)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612586
The ClinicalTrials.gov registry entry for NCT00612586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00612586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612586 about?
NCT00612586 is a clinical study titled "Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer". This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV + irinotecan (FOLFIRI), plus bevacizumab in patients...
What is the current status of trial NCT00612586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2008-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00612586?
The interventions under investigation include: Placebo (DRUG), Leucovorin (LV) (DRUG), 5-fluorouracil (5-FU) (DRUG), Enzastaurin (DRUG), Bevacizumab (Bev) (DRUG).
Who is sponsoring clinical trial NCT00612586?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.